Laura Rivers-Bowerman

Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011.